2027 Medicare Advantage and Medicare Prescription Drug Programs
Article Publication Date
Summary
CMS recently released plan information for the 2027 Medicare Advantage (MA) and Medicare prescription drug programs.
According to CMS, the total average monthly Part D premium for stand-alone prescription drug plans nationwide is projected to increase by less than $1, from $35.09 in 2026 to $36 in 2027. 88% of non-low-income beneficiaries will have access to a basic Part D plan costing $10.30 or less, and 93% of non-low-income beneficiaries will have access to an enhanced Part D plan costing less than $6.00.
For MA plans that include prescription drug coverage, after application of MA rebates, the average monthly Part D total premium is projected to decrease from $11.32 in 2026 to $7 in 2027, a decrease of $4.32 or 38%. The weighted average monthly premium across all MA plans, including plans with prescription drug coverage and Special Needs Plans, is projected to decrease from $14.37 in 2026 to $12.00 in 2027, a 16.5% decline. Supplemental benefit offerings, including hearing, dental, and vision benefits, are expected to remain stable.
According to CMS, the total average monthly Part D premium for stand-alone prescription drug plans nationwide is projected to increase by less than $1, from $35.09 in 2026 to $36 in 2027. 88% of non-low-income beneficiaries will have access to a basic Part D plan costing $10.30 or less, and 93% of non-low-income beneficiaries will have access to an enhanced Part D plan costing less than $6.00.
For MA plans that include prescription drug coverage, after application of MA rebates, the average monthly Part D total premium is projected to decrease from $11.32 in 2026 to $7 in 2027, a decrease of $4.32 or 38%. The weighted average monthly premium across all MA plans, including plans with prescription drug coverage and Special Needs Plans, is projected to decrease from $14.37 in 2026 to $12.00 in 2027, a 16.5% decline. Supplemental benefit offerings, including hearing, dental, and vision benefits, are expected to remain stable.